Drug intelligence / Profile preview

F61

Development stage: Phase 1
Lead developer: Wuhan Institute of Biological Products
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Injection, Intranasal

Overview

F61 is a recombinant human monoclonal antibody developed by Wuhan Institute of Biological Products as an inhibitor of the SARS-CoV-2 spike (S) protein, targeting the coronavirus responsible for COVID-19. It has been evaluated in clinical trials for its efficacy in preventing and treating COVID-19, with studies showing significant efficacy in multiple-dose cohorts. The drug is administered as an injection or nasal spray. Its primary mechanism of action is inhibition of the SARS-CoV-2 spike glycoprotein, thereby blocking viral entry into host cells.

Other names: F 61F61F-61

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on F61.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F61.

Explore the full profile